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Background
Lung cancer, the most common cause of cancer death in both 
men and women in the United States, has a 15% overall 5-year 
survival rate1—a survival rate that has not changed significantly 
in more than 20 years. Lung cancer is strongly associated with 
cigarette smoking, an association known since the Surgeon 
General’s Report of 1954, if not before; however, public health 
measures to abolish tobacco exposure have failed. Therefore, 
new novel therapeutic agents must be quickly introduced and 
rapidly evaluated for effectiveness. Although such developments 
have begun,2 therapeutic response assessment has failed to keep 
pace with potential therapeutic advances.
In the late 1970s, the National Institutes of Health supported 
an examination of screening for lung cancer in at-risk popula-
tions using sputum cytology and chest radiographs;3–5 these 
early screening studies failed to demonstrate a mortality benefit. 
Current studies are under way to reevaluate screening using 
improved sputum tests, multidetector computed tomography 
(MDCT), and, in some cases, bronchoscopy with special bron-
choscopes to detect subtle differences in airway mucosal fluo-
rescence.6 The MDCT studies, most notably the Early Lung 
Cancer Action Project,7 the Mayo Clinic study,8 and studies in 
Japan,9 have provided important information regarding lung 
cancer detection. More recently, the National Lung Screening 
Trial,10 a multicenter, National Institutes of Health–funded 
study involving nearly 50,000 at-risk smokers (half randomized 
to chest radiographs, the other half to MDCT), has met its 
accrual target.
Despite the sensitivity of MDCT, it is difficult to discriminate 
the early signs of malignancy on MDCT from the much more 
common benign processes, both of which appear as lung nod-
ules; this is especially difficult in regions of the United States 
where fungal diseases such as histoplasmosis are endemic. Only 
a small fraction of detected lung nodules are indeed cancer. The 
current standard of care for a detected small nodule (<8 mm in 
diameter) is a repeat MDCT scan in 3 months and subsequently 
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Critical to the clinical evaluation of effective novel therapies for lung cancer is the early and accurate determination of 
tumor response, which requires an understanding of the sources of uncertainty in tumor measurement and subsequent 
attempts to minimize their effects on the assessment of the therapeutic agent. The Reference Image Database to Evaluate 
Response (RIDER) project seeks to develop a consensus approach to the optimization and benchmarking of software 
tools for the assessment of tumor response to therapy and to provide a publicly available database of serial images 
acquired during lung cancer drug and radiation therapy trials. Images of phantoms and patient images acquired under 
situations in which tumor size or biology is known to be unchanged also will be provided. The RIDER project will create 
standardized methods for benchmarking software tools to reduce sources of uncertainty in vital clinical assessments 
such as whether a specific tumor is responding to therapy.
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at 3-month or 6-month intervals to assess growth of the nodule. 
Consequently, early detection is not translated into early diag-
nosis and early treatment, a phenomenon known as the lung 
cancer paradox (i.e., early detection of lung cancer is possible, 
but early treatment is not). Increasing precision of transcutane-
ous needle sampling and increasing yields from bronchoscopic 
biopsies with the assistance of 3D computer-generated graphics, 
magnetic guidance, and magnetic tracking devices are helping 
to resolve this paradox.11
Currently the best hope of lung cancer cure is surgical resec-
tion of a small peripheral lung nodule, which is currently pos-
sible in about 15% of patients presenting with early-stage disease 
(the other patients present with later-stage disease or are not sur-
gical candidates because of comorbidities). Patients who are not 
able to receive surgery are often treated with chemotherapy, with 
or without associated external beam radiotherapy. Treatment 
protocols vary across the country and may include group proto-
col studies and clinical trials. New biological response modifiers 
for lung cancer therapy have drawn increased interest recently. 
These generally less-toxic agents are targeted to affect the tumor 
blood supply or other critical pathways in cancer cell growth, 
differentiation, or metastatic processes. The end point of such 
therapies may not be lung cancer “disappearance” but rather 
tumor growth cessation.
Strategies for disease-response assessment must accommodate 
a wide range of treatment options. For example, subtle changes 
in the lung cancer CT density, margins, or other pixel-based 
features may signal a useful response at an early stage of therapy. 
Blood flow may be an important measure for tumor vascula-
ture–based changes, and metabolic changes may be measured by 
positron emission tomography (PET). Critical to image-based 
evaluation of either tumor growth or response to therapy is a 
much-improved understanding of the 3D anatomic/pathologic 
structure of lung cancer. Assessments based on 2D pathology 
slides indicate that malignant cells occupy only a fraction of a 
lung nodule’s volume, with the remainder consisting of inflam-
matory cells, edema, fibrosis, or necrosis. Understanding the 3D 
structure of lung cancer pathologically is critical to the evalua-
tion of 3D imaging modalities. Future response-assessment pro-
tocols could then specifically target the lung cancer component 
of a lung nodule or biomass.
The current standard method to measure tumor response 
using CT and other modalities is referred to as Response 
Evaluation Criteria in Solid Tumors (RECIST), which is based 
on unidimensional, linear measurements of tumor diameter.12,13 
Via a summed linear measurement of a limited number of target 
tumors, RECIST offers a simple approach that requires minimal 
effort. The RECIST guidelines, however, presume that tumors are 
spherical and change in a similar manner. Significant variabil-
ity in the RECIST measures exists among different observers,14 
and published work generally focuses on the surrogate of “best 
overall response,” with only a few methods addressing other 
imaging end points such as “time to progression” and “disease-
free survival.” As a therapy-response measurement procedure, 
RECIST maps linear data into an established set of four discrete 
categories: complete response, partial response, stable disease, 
and progressive disease. These categorical bins, however, are 
quite coarse, with most trial analyses critically pivoting on par-
tial response (defined by a 30% linear sum reduction) and pro-
gressive disease (defined by a 20% increase in tumor dimension). 
Furthermore, if the lung cancer volume is mostly inflamma-
tion, then linear size change alone may give a false impression 
of therapy response (e.g., the inflammation was reduced, but 
the cancerous component was not); in fact, a tumor may slightly 
increase in size after initiation of therapy as a result of inflam-
matory reactions. With newer chemotherapeutic agents and 
radiotherapy techniques, change in tumor diameter may be 
inadequate to assess response. Therefore, to improve the assess-
ment of time to response and to reduce observer variation, other 
parameters such as attenuation changes, margin-contour altera-
tions, or pixel intensity changes across temporally sequential 
CT scans will be required, especially as improved imaging tech-
niques and registration methods become available.
In this article we summarize a recent initiative to develop a 
consensus approach to the benchmarking of software tools for 
the assessment of tumor response to therapy and to provide a 
publicly available database of images and associated metadata. 
The Reference Image Database to Evaluate Response to therapy 
in lung cancer (RIDER) project is generating a database of tem-
porally sequential CT scans (and other imaging modalities) of 
lung cancer subjects collected longitudinally over the course 
of nonsurgical cancer therapy. The database will also include 
phantom images of synthetic lung nodules and short-interval 
patient scans for the evaluation of the variance and bias of 
change-analysis software tools. This project evolved from the 
Lung Image Database Consortium (LIDC), which is creating a 
publicly available database of annotated thoracic CT scans as a 
reference standard for the development, training, and evaluation 
of computer-aided diagnostic methods for lung cancer detection 
and diagnosis.
rider Project
The RIDER project was initiated in 2004 as a collaboration 
among the National Cancer Institute (NCI)’s Cancer Imaging 
Program, the NCI’s Center for Bioinformatics, the National 
Institute of Biomedical Imaging and Bioengineering, and the 
Cancer Research and Prevention Foundation, with informa-
tion technology support from the Radiological Society of 
North America. The RIDER project was designed, and contin-
ues to evolve, through a consensus process among members 
of the RIDER steering committee, which includes academic 
researchers, program staff at NCI, and members of the 
Cancer Biomedical Informatics Grid, the National Institute of 
Biomedical Imaging and Bioengineering, the US Food and Drug 
Administration (FDA), and the National Institute of Standards 
and Technology. The broad purpose of the RIDER project is 
to develop a public resource of serial (i.e., temporally sequen-
tial) images acquired during the course of various lung cancer 
drug and radiation therapy trials across multiple  centers so that 
change-analysis software tools may be optimized and bench-
marked before use in future trials. The data, which will be avail-
able to academic researchers and the device and pharmaceutical 
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industries, will include images from CT and other modalities 
such as PET/CT and magnetic resonance imaging, along with 
relevant metadata and clinical outcomes. Images of physical 
phantoms and patient images acquired under situations in 
which tumor size or biology is known to be unchanged (in 
which the “true” change is known) will also be provided and 
will play a key role in the assessment of software-tool perform-
ance. The RIDER project will highlight the importance of creat-
ing standardized methods for benchmarking software tools to 
reduce sources of uncertainty in vital clinical assessments such 
as whether a specific tumor is responding to therapy.
The longer-term goal of RIDER is to help identify biomark-
ers to measure cancer therapy response. Such biomarkers could 
potentially be adopted in clinical trials submitted to the FDA for 
regulatory approval. In addition, the Centers for Medicare and 
Medicaid Services seeks evidence to support informed reim-
bursement decisions for biomarkers that may eventually be 
used clinically. Consequently, the RIDER project is expected to 
accelerate FDA approval of software-based response-assessment 
tools (and therapeutic agents evaluated through clinical trials 
that use such tools) and Centers for Medicare and Medicaid 
Services reimbursement for subsequent therapeutic decisions 
made using such software tools.
New therapies are clearly needed for lung cancer, and indeed 
new therapies have been, and continue to be, developed by the 
pharmaceutical industry and through National Institutes of 
Health–funded academic research. Critical to the clinical evalu-
ation of effective novel therapies is the early and accurate deter-
mination of tumor response, which would substantially reduce 
the numbers of subjects in clinical trials, the duration of trials, 
and the costs. Critical to the early and accurate determination of 
tumor response, however, is an understanding of the sources of 
uncertainty in these tumor-response measurements, with subse-
quent attempts to minimize their effect on the assessment of novel 
therapeutic agents. Measurement variability is associated with two 
interrelated factors: (i) the different commercial systems used to 
acquire images and (ii) the different image-analysis software tools 
used to measure temporal changes in image features. The devel-
opment of standardized methods to physically characterize these 
two sources of uncertainty would stimulate the development of 
both improved imaging methods and software tools.
Toward this end, the RIDER project will evaluate change-anal-
ysis software tools by testing their relative performance against 
a validated and standardized reference database.
data-collection Process
Numerous government-sponsored or privately sponsored 
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Figure 1 Radiological Society of North America Medical Imaging Resource 























































































Figure 2 Cancer Biomedical Informatics Grid and National Cancer Imaging Archive infrastructure that incorporates Radiological Society of North 
America Medical Imaging Resource Center (MIRC) software for remote data collection that is compatible with the Digital Imaging and Communications 
in Medicine format.
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at multiple time points before, during, and after cancer therapy 
to accurately capture changes in tumor size that may provide a 
useful indication of  disease progression or response to therapy. 
CT, PET/CT, and magnetic resonance images in Digital Imaging 
and Communications in Medicine format from such trials are 
currently being collected from lung cancer patients across mul-
tiple centers by use of the Radiological Society of North America 
Medical Imaging Resource Center software (an open-source soft-
ware suite for use in clinical trials) (Figure 1), thus ensuring that 
the collected images meet all de-identification and patient-confi-
dentiality requirements. Many trials sponsored by NCI’s Cancer 
Therapy Evaluation Program, for example, use network-connected 
imaging devices capable of transmitting de-identified images to 
a central archive in Digital Imaging and Communications in 
Medicine standard format. These cases are being annotated by 
multiple observers based on the RECIST guidelines. The images, 
annotations, and associated metadata are being transferred to 
a web-accessible, scalable, secure archive (the National Cancer 
Imaging Archive) (Figure 2) that provides public access to the 
database and allows interactive search, display, and downloading 
of images and metadata (Figure 3). Appropriate patient-outcomes 
data will be provided so that users of the database may correlate 
change-analysis results with outcomes.
The RIDER data-collection process initially targeted serial 
MDCT scans from lung cancer patients undergoing systemic 
chemotherapy treatment for late-stage disease so that few would 
have undergone the localized anatomy-distorting effects of radi-
otherapy or surgery. Each patient had a baseline diagnostic CT 
scan followed by temporally sequential scans throughout the 
course of therapy. Selected scans excluded hardware or major 
artifacts such as breathing motion. Scans may demonstrate more 
than one tumor, thus allowing end users to choose the target 
lesion or lesions most representative of the disease (analogous 
to the approach adopted by the RECIST method).
The database will include detailed descriptions of modality-
specific acquisition parameters that could potentially influence 
the accurate measurement of change in tumor morphology 
(e.g., diameter or volume) or functional parameters (e.g., active 
tumor volume or tumor perfusion). For CT imaging, the values 
of several key image-acquisition parameters are included in the 
database: (i) CT scanner make, model, and technical capabilities; 
(ii) scanning protocol (a static, single-breath-hold protocol or a 
dynamic protocol to obtain a series of scans performed before 
and after contrast agent injection); (iii) technical parameters such 
as the slice thickness, X-ray beam energy, tube current, tube rota-
tion time, pitch, reconstruction algorithm, and reconstruction 
Figure 3 The National Cancer Imaging Archive website containing the RIDER data.
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interval; and (iv) contrast agent information. For PET/CT, the 
image- acquisition parameters of the CT are collected along with 
relevant technical parameters for the PET scan component: (i) 
concentration and dose of the radiopharmaceutical; (ii) timing of 
the scan and extent of anatomy imaged; and (iii) parameters such 
as the reconstructed slice width, attenuation correction methods, 
and gating methods to reduce motion artifacts. In addition, a 
description of the PET/CT fusion algorithm will be included, 
if applicable. Magnetic resonance images require information 
regarding: (i) imaging protocol (static breath-hold or continu-
ous breathing or dynamic scan); (ii) technical parameters such 
as the imaging sequence used (e.g., T1 or T2 weighting); and (iii) 
information about inhaled (e.g., hyperpolarized xenon gas) or 
injected contrast agents.
The RIDER database initially focused on CT scans with the 
following specifications: (i) slice thickness ≤7.5 mm (with thick-
ness ≤2.5 mm preferred); (ii) single breath-hold scans; (iii) at 
least two (and preferably three) scans per patient to assess tumor 
progression or response to therapy, with the earlier scan pre-
ferred at baseline and including measurable disease; (iv) patient 
must be on a chemotherapeutic and/or a radiation therapy treat-
ment protocol for histologically proven primary lung cancer 
(preferred) or metastatic disease to the lung; (v) with or without 
contrast agent. The RIDER project is now collecting scans with 
thin slices (≤1.25 mm) to allow more accurate estimates of tumor 
diameter, volume, and other morphological descriptors. Some 
example images reconstructed with different slice thicknesses 
and reconstruction algorithms are shown in Figures 4 and 5 
to illustrate the effect of these parameters on image quality and 
lesion appearance and to reflect the potential of these parame-
ters to affect reliable measurement of tumor volume. The lesions 
captured in the database will reflect a representative variety of 
lesion size, morphology, margin characteristics, internal struc-
ture, and anatomic location (including lesions isolated within 
the lung and lesions adjacent to or invading nearby structures). 
Collected patient information includes descriptions of standard 
demographics (gender/age), smoking history, histological tumor 
type, clinical stage, and current and interval therapy. Clinical 
outcome data will be added when available.
The collection of data for the RIDER project is modeled after the 
data-collection process of the NCI-sponsored LIDC,15–17 which 
required the collection of de-identified images, the annotation 
of those images by expert radiologists, and the addition of other 
demographic and clinical data from five academic sites, followed 
by the archiving of the cases in a publicly available, searchable 
archive. Although the RIDER project has objectives that differ 
from those of the LIDC, much of the data-collection process from 
LIDC has been adapted to the needs of the RIDER database.
One of the key elements of the LIDC database was to pro-
vide detailed information about the location and spatial extent 
of lung nodules based on radiologists’ interpretations of the 
images; however, considerable inter-reader variability exists 
in the detection of lung nodules in CT scans.18,19 Instead of 
a forced consensus–based approach, the LIDC developed a 
process that would provide the best estimate of the radiologists’ 
interpretations while capturing variability among the readers. 
The result was a data-collection process that utilized multiple 
readers independently performing two readings of each case. To 




Figure 4 Differences in image quality and lesion appearance due to changes 
in slice thickness. Axial (left) and coronal (right) images of a patient during a 




Figure 5 Differences in image quality and lesion appearance due to changes 
in reconstruction algorithm. Axial (left) and coronal (right) images of a patient 
during a single scan with 2-mm thickness and (a) a smooth reconstruction 
algorithm and (b) a sharp reconstruction algorithm.
ClInICal phaRmaCology & ThERapEuTICs | VOLUME 84 NUMBER 4 | OCTOBER 2008 453
state          art
asynchronous process executed across geographically dispa-
rate sites, the LIDC developed software tools to mark lesions 
with manual or semiautomated contouring tools. The LIDC 
also developed of a common XML-based file format to contain 
detailed  descriptions of nodule attributes (such as boundaries 
and characteristics) that was portable across institutions and 
software tools. This infrastructure provides a mechanism for 
image collection and for the acquisition of radiologists’ inter-
pretations of the images. The stored representation of a lung 
nodule or mass for the RIDER project can take the form of either 
a single RECIST-based diameter or detailed outlines in every CT 
section that contains the lesion, from which volume or longest 
diameter subsequently may be derived.20 These data will serve 
as input to computerized systems designed to assess changes 
indicative of a lesion’s response to therapy.
results From the lidc
Whereas the LIDC requires accurate segmentation of nodules, 
the RIDER project requires the accurate measurement of nod-
ule change over time. Both missions require an understanding 
of variability in defining the spatial extent of lung nodules by 
radiologists using different software tools. As part of the LIDC 
effort, a study investigating the variability of boundaries across 
radiologists and drawing methods was performed.21 In this 
study, the performance of six radiologists applying three differ-
ent outlining methods to the task of defining the spatial extent of 
23 lung nodules was evaluated. The drawing methods consisted 
of one entirely manual method and two semiautomatic draw-
ing methods with manual editing tools. The variability of the 
radiologists’ spatial definitions for a nodule was measured using 
both volumes and probability maps (p-maps), where the value of 
a pixel in the p-map represents a spatially smoothed estimate of 
the fractional number of radiologist–method combinations that 
included that specific pixel within their boundary definition of 
the nodule. Differences in volume and p-map model parameters 
were found to be significant for all methods, all radiologists, and 
all second-order interactions except one across the 23 nodules. 
The radiologist and method variables accounted for 15 and 3.5% 
of the total p-map variance, respectively, and 40.4 and 31.1% of 
the total volume variance, respectively. In the critical process of 
segmenting lung nodules, radiologist variance was 4 times that 
of the method used, and in the related assessment of nodule vol-
umes, radiologist variance was 1.3 times that of the method.
A subsequent LIDC study went beyond variability in the actual 
radiologist contours and evaluated the variability that resulted 
from a reduction of those contours to an estimate of nodule size 
that might be used clinically.20 With a collection of 518 lung nod-
ules contoured by at least one of the four LIDC radiologists (of 
which 127 had been contoured by all four radiologists), substan-
tial interobserver variability was observed for a unidimensional, a 
3D, and two different bidimensional size metrics. Moreover, large 
differences were observed among the size metrics.
Volume-change measurement
The RIDER project has crafted a series of studies that will eval-
uate change in nodule volume from the perspective of bias and 
variance. The goal of these studies is to define the parameters 
by which software tools should be benchmarked, evaluated, 
and compared so that their eventual inclusion in clinical trials 
will be accompanied by statistical confidence that real lesion 
change may be identified at the soonest possible time point. 
For example, tools with lower variance will enable the reliable 
detection of smaller changes in nodule volume. These stud-
ies will be performed by multiple radiologists using multiple 
tools, because a single radiologist using a single tool will likely 
demonstrate less variance than that measured across different 
tools. In addition, multiple repetitions of the same radiologist–
tool combinations will be performed to estimate intra- and 
interobserver effects.
Change-detection methods evaluated across serial CT scans 
will include the current standard of practice (the manual 
RECIST method), automated/semiautomated tumor segmen-
tation methods, and methods based on supervised automated 
tumor registration techniques. Registration techniques include 
local rotate–translate registration followed by grayscale weighted 
subtraction and high degree-of-freedom warping followed by 
integration of the Jacobian matrix. Although the initial approach 
will focus on anatomic imaging and tumor volumetrics, other 
nonvolumetric techniques for evaluating response to therapy 
will be evaluated, including functional imaging (e.g., perfusion 
and magnetic resonance diffusion).
Before evaluating volume-change-analysis software on images 
acquired from a clinical trial, two fundamental properties of the 
software—bias and variance—must be understood and quanti-
fied. The assessment of bias error (i.e., error in the measurement 
of average accuracy) will include multiple scans of phantoms 
containing objects of known volume change and scans modi-
fied using known mathematical geometric deformations. The 
assessment of variance (i.e., measurement noise that results in 
the reduction of sensitivity in the detection of a small volume 
change) will include data sets in which, to a reasonable level of 
certainty, no macroscopic changes in the nodule have occurred. 
Given that the most immediate goal of RIDER is the early detec-
tion of volume changes or functional changes in a nodule or 
lung mass that might predict therapeutic outcomes, the highest-
priority study is the assessment of variance for different change-
analysis software tools applied to nodules with no observable 
change. Examples of such “no-change” scenarios include mul-
tiple short-interval scans (with appropriate institutional review 
board approval) of patients with nodules of varying size and 
complexity. During these so-called “coffee-break studies,” the 
patient is imaged once, gets off and then back on the scanner 
table, and a second scan is acquired. Differences between the 
first and second set of images would presumably result only 
from patient positioning differences and noise introduced by the 
scanner. These coffee-break study images, which have already 
been obtained for a number of patients with CT and with PET, 
establish the null hypothesis from which the effect size of true 
change must be distinguished. In other words, knowledge of sys-
tem variance allows for a determination of whether a measured 
change likely represents an actual change in tumor volume or, 
instead, likely results from noise in the measurement system.
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Once the variance has been approximated, the number of 
observations (i.e., measurements of volume change) that must 
be obtained to test for the presence of a bias effect at some stated 
level of significance can be determined. The required number 
of observations increases as the size of the bias to be measured 
decreases, the measured variance increases, and the power (i.e., 
the likelihood of detecting the change at the given level of sig-
nificance) increases. Because variance and bias may have an 
interaction with nodule size (along with other factors, such as 
nodule shape, nodule type, and image acquisition/reconstruc-
tion protocol), variance and bias measurements eventually will 
be made using nodules demonstrating a spectrum of volumes 
and characteristics.
The determination of bias in the presence of true volume change 
is needed to complete the statistical characterization of a meas-
urement method. If bias is estimated only under the no-change 
scenario, then only a binary form of accuracy will be evaluable, 
namely, whether or not change is present. The truth data required 
to quantify volume change, however, are more difficult to obtain. 
In fact, estimates of bias in volume change may be dependent on 
the extent of volume change itself. The only way to obtain images 
with known size-change “truth” is to scan physical phantoms with 
known nodule characteristics and different sizes. The concern 
with this method, however, is the ability of phantoms to accu-
rately represent real lung nodules and the surrounding anatomic 
background from the perspective of the imaging modality under 
investigation. A method for obtaining volume-change truth for 
actual nodules has yet to be defined. The closest approximation 
to truth for actual nodules is image-based measurements made 
by expert radiologists, but this approach is itself subject to bias 
and substantial variance20,21 and thus is not useful. The RIDER 
project, through interactions with the FDA, is obtaining both 
scans of phantom images with a variety of artificial nodules and 
clinical scans with manual observer measurements of actual lung 
nodules to investigate these important issues.
standardized methods For soFtware  
PerFormance eValuation
The RIDER project is designing the approach with which the 
performance of software tools will be benchmarked and evalu-
ated. Factors being explored include image sequestration, gov-
ernorship and maintenance of the archive, and training set and 
evaluation set requirements. Users of software diagnostic tools 
for lung cancer need confidence in the performance of the algo-
rithms when applied to the broad variety of images that will be 
encountered in a clinical setting. The application of the tools to 
images distinct from those on which the tools were developed 
demonstrates that performance is not the result of tuning to a 
particular collection of cases. To this end, a set of evaluation 
cases that is distinct and independent from the training set will 
be established. Before system evaluation, the training set, includ-
ing all annotations, will be available to the algorithm developers, 
whereas the evaluation set is sequestered and is available only 
to an independent evaluation team. The developers of software 
tools will have access to the sequestered images and associated 
annotations once an evaluation is complete to better understand 
performance and to improve the tools; therefore, the sequestered 
evaluation set will need a continuous influx of new scans as cases 
migrate into the training (open) portion of the archive.
comPlementary initiatiVes
A number of projects that complement the broader goals 
of RIDER have been initiated. An NCI-sponsored funding 
opportunity (PAR-07-214, “Academic-Industrial Partnerships 
for Development and Validation of In Vivo Imaging Systems 
and Methods for Cancer Investigations”) has been issued as an 
R01 funding mechanism. The primary focus of this PAR is to 
enhance translational research for targeted clinical investiga-
tions, one goal of which is the development of public resources 
to accelerate translational research and the creation of standard-
ized methodologies for data acquisition and analysis.
The Uniform Protocols for Imaging in Clinical Trials effort 
seeks to develop guidelines for uniform image acquisition pro-
tocols in clinical trials through a consensus process of diagnostic 
radiologists, radiation oncologists, medical physicists, clinical 
trial experts, government agency representatives, and appro-
priate industry representatives. Uniform Protocols for Imaging 
in Clinical Trials was conceptualized by the American College 
of Radiology and the NCI to address the need for consistent 
imaging protocols used in multisite clinical trials to improve 
the reproducibility of quantitative image data obtained from the 
many sites required for patient accrual.
The Clinical Trials Working Group was established by the NCI 
director to evaluate how the national clinical trials enterprise 
should be restructured to realize the promise of molecular medi-
cine for advancing oncologic clinical practice. The Clinical Trials 
Working Group was a broadly constituted panel with experts 
from academic research institutions, community oncology 
practices, the pharmaceutical and biotechnology industries, 
cancer patient advocacy groups, the NCI, the FDA, and the 
Centers for Medicare and Medicaid Services. One of the goals 
defined by the Clinical Trials Working Group was improved 
standardization of tools and procedures for trial design, data 
capture, and data sharing to minimize duplication of effort. The 
Clinical Trials Working Group recognized that the evaluation of 
novel targeted therapies depends on the synergistic integration 
of treatment protocols with modern molecular diagnostic and 
imaging techniques.
The NCI Image Response Assessment Team program is 
designed to advance the role of imaging in the assessment of 
response to therapy. The long-term objective of this program 
is to increase clinical collaboration between imaging scientists 
and oncologic investigators at cancer centers. The teams are 
identifying new oncologic imaging research opportunities in 
clinical trials that warrant multicenter investigations and plan 
to integrate imaging data as a potential biomarker or candidate 
surrogate marker in clinical therapeutic trials.
conclusions
One recurring and very significant issue in the evaluation of 
new therapies, such as those for nonsurgically treated lung 
cancer, is the assessment of response to therapy. Establishing 
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therapy safety and effectiveness is essential for therapy regula-
tory approval and for third-party payers to approve payments 
for that therapy. The current approval metric, however, is based 
on patient survival compared against a “best therapy” standard 
in a randomized controlled study. Such studies are expensive in 
terms of both time and money. Moreover, because such studies 
may require large numbers of subjects, the commencement of 
one study means that other promising therapeutic agents are 
never tested. Such an approach therefore denies the general 
population access to many potentially useful agents.
The RIDER project is an important step in replacing this old 
paradigm with a consensus-based process of developing well-
 defined image-based metrics to measure tumor-specific response 
as the primary outcome. This will allow many more therapeutic 
agents to be tested more rapidly, either singly or in combination, 
with large cost savings and without detriment to subject safety. 
A final randomized controlled study with patient survival as the 
end point may still be needed for final regulatory approval, but 
such a study then may be performed with knowledge that the 
best available therapy has been chosen for evaluation.
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